Italian Undersecretary of State Lauds Collaboration
Oct. 23, 2006 06:05 PM
TORONTO -- (MARKET WIRE) -- 10/23/06 -- On October 20, 2006, Generex Biotechnology
Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic
diseases through the inner lining of the mouth, together with University
Campus Bio-Medico of Rome, Italy, hosted a symposium as an adjunct to the
Canadian Diabetes Association Professional Conference and Annual Meetings
in Toronto, Canada.
The well-attended symposium was entitled "Diabetes Mellitus and the
Changing Landscape of Treatment" and featured the following speakers: Dr.
Gerald Bernstein, the Company's Vice-President for Medical Affairs; Dr.
Jaime Davidson, the Company's Medical Director; Dr. Breay Paty, an
Assistant Professor in the Division of Endocrinology & Metabolism of the
University of Alberta Department of Medicine; and Professor Paolo Pozzilli
of the Department of Endocrinology and Diabetes at University Campus
Bio-Medico.
The symposium took place at the MaRS Discovery District in downtown
Toronto, a facility located on the very site of a landmark medical
breakthrough -- the discovery of insulin. The MaRS Discovery District is a
globally significant facility designed to foster research and innovation
and take discoveries from the lab to the marketplace. The MaRS Discovery
District brings together best-in-class science with business and capital,
creating opportunities for these communities to come together. Leading
researchers in diverse fields such as medical sciences, biotechnology,
biopharmaceuticals, pharmaceuticals and information technology can connect
to technology companies, business services firms, funding agencies and
venture capitalists under one roof to turn ideas into products and
partnerships.
Following the symposium, Mr. Gabriele Sardo, the Ambassador of Italy to
Canada, held a press conference to laud the long and productive
collaboration between Generex and Italy's University Campus Bio-Medico.
Under the supervision of Professor Paolo Pozzilli, a world-renowned
endocrinologist and diabetes investigator, University Campus Bio-Medico
undertook some of the early groundbreaking clinical trials of Generex
Oral-lyn(TM), Generex's proprietary oral insulin spray product designed to
replace prandial injections of insulin.
At the press conference, Undersecretary of State the Honourable Vittorio
Michele Craxi of the Italian Ministry of Foreign Affairs also praised the
collaboration and hailed the important work of Generex and Campus
Bio-Medico and the prospects for fundamentally improving the lives of
patients with diabetes.
About Generex
Generex is engaged in the research and development of drug delivery systems
and technologies. Generex has developed a proprietary platform technology
for the delivery of drugs into the human body through the oral cavity (with
no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the
body by the lining of the inner mouth using the Company's proprietary
RapidMist(TM) device. The Company's flagship product, oral insulin
(Generex Oral-lyn(TM)), which is available for sale in Ecuador for the
treatment of patients with Type-1 and Type-2 diabetes, is in various stages
of clinical trials around the world. For more information, visit the
Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to
time by Generex representatives concerning the same subject matter may
contain "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements can be
identified by introductory words such as "expects," "plans," "intends,"
"believes," "will," "estimates," "forecasts," "projects" or words of
similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Forward-looking statements frequently are
used in discussing potential product applications, potential
collaborations, product development activities, clinical studies,
regulatory submissions and approvals, and similar operating matters. Many
factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known
risks and uncertainties include those identified from time to time in the
reports filed by Generex with the Securities and Exchange Commission,
which should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and
one should avoid placing undue reliance on such statements. Generex cannot
be sure when or if it will be permitted by regulatory agencies to undertake
additional clinical trials or to commence any particular phase of clinical
trials. Because of this, statements regarding the expected timing of
clinical trials cannot be regarded as actual predictions of when Generex
will obtain regulatory approval for any "phase" of clinical trials.
Generex claims the protection of the safe harbor for forward-looking
statements that is contained in the Private Securities Litigation Reform
Act.
.gif)
